Intensity Therapeutics Q1 net loss narrows on lower R&D costs

Intensity Therapeutics

07/05/2026 22:00

Overview

US biotech firm's Q1 net loss narrowed yr/yr on lower R&D expenses

Company ended Q1 with $10.2 mln in cash and cash equivalents

Plans to resume enrollment in INVINCIBLE-3 and INVINCIBLE-4 clinical trials in 2026

Outlook

Intensity Therapeutics plans to resume INVINCIBLE-4 Study enrollment in Switzerland in Q2 2026

Company expects to initiate INVINCIBLE-4 Study enrollment in France in Q2 or Q3 2026

Intensity Therapeutics will resume INVINCIBLE-3 Study enrollment in limited U.S. sites by Q3 2026

Result Drivers

LOWER R&D SPENDING - Research and development expenses fell due to reduced costs from pausing new site activations and patient enrollment in the INVINCIBLE-3 study

EARLY TRIAL DATA - Preliminary results from the INVINCIBLE-4 study showed higher pathological complete response rates and fewer severe adverse events for INT230-6 plus standard of care compared to standard of care alone

Company press release: ID:nPnbRhMP0a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Basic EPS
-$0.96
Q1 Operating Income
-$2.53 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Intensity Therapeutics Inc is $31.00, about 495% above its May 6 closing price of $5.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)